+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Hallucinations caused by paroxetine in combined usage of levodopa-carbidopa



Hallucinations caused by paroxetine in combined usage of levodopa-carbidopa



Nederlands Tijdschrift Voor Geneeskunde 146(22): 1056-7; Author Reply 1057




(PDF emailed within 1 workday: $29.90)

Accession: 046210070

Download citation: RISBibTeXText

PMID: 12073510


Related references

Hallucinations caused by paroxetine taken together with a levodopa-carbidopa preparation. Nederlands Tijdschrift Voor Geneeskunde 146(12): 574-575, 2002

Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)). Journal of Clinical Pharmacology 55(9): 995-1003, 2016

Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. Clinical Neuropharmacology 32(4): 189-192, 2009

Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study. Journal of Neural Transmission 117(3): 333-342, 2010

Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. European Journal of Clinical Pharmacology 65(5): 443-455, 2009

Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers. Clinical Neuropharmacology 35(3): 111-117, 2013

Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease. Neurology 25(10): 911-916, 1975

Early-morning akinesia in Parkinsons disease Effect of standard carbidopa/levodopa and controlled-release carbidopa/levodopa. Neurology 45(4 SUPPL 4): A252, 1995

Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. Neurology 46(4): 1059-1062, 1996

Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients. Aaps Journal 15(2): 316-323, 2013

Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures. Movement Disorders 12(5): 677-681, 1997

Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. Journal of Neural Transmission 114(11): 1457-1462, 2007

Plasma levels of levodopa. Its main metabolites and carbidopa after conventional and slow release levodopa-carbidopa treatment in parkinsonian patients. Pharmacological Research 22 Suppl 1: 119-120, 1990

Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Movement Disorders 24(4): 541-550, 2008

Standard Carbidopa-Levodopa versus controlled-release Carbidopa-Levodopa in Parkinson's disease: A postmarket analysis. Clinical Neuropharmacology 17(2): 128-137, 1994